Nanoformulated cell-penetrating survivin mutant and its dual actions

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3279-3298

  Sriramoju, Bhasker ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Inhibitor of apoptosis protein family; Neurological disorders; Poly(lactic co glycolic acid); Protein therapeutics; Survivin mutant

Indexed keywords

BROXURIDINE; CASPASE 3; CELL PENETRATING PEPTIDE; CYCLINE; FLUORESCEIN ISOTHIOCYANATE; KI 67 ANTIGEN; LIPOCORTIN 5; NANOPARTICLE; POLYGLACTIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; REPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PURIFICATION; DRUG RELEASE; DRUG UPTAKE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SURFACE PROPERTY; WILD TYPE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; MOUSE; MUTATION; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MUTATION; NANOPARTICLES; REPRESSOR PROTEINS;

EID: 84904321261     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S60169     Document Type: Article

References (68)

1. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21(8):2661-2668.
2. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders how to make it work. Nat Med. 2004;10 Suppl:S42-S50.
3. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain. 2004;127(Pt 6):1313-1331.
4. Jiang Y, de Bruin A, Caldas H, et al. Essential role for survivin in early brain development. J Neurosci. 2005;25(30):6962-6970.
5. Kanwar RK, Cheung CH, Chang JY, Kanwar JR. Recent advances in anti-survivin treatments for cancer. Curr Med Chem. 2010;17(15):1509-1515.
6. Xu D, Bureau Y, McIntyre DC, et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci. 1999;19(12):5026-5033.
7. Baratchi S, Kanwar RK, Kanwar JR. Survivin: a target from brain cancer to neurodegenerative disease. Crit Rev Biochem Mol Biol. 2010;45(6):535-554.
8. Makrantoni V, Stark MJ. Efficient chromosome biorientation and the tension checkpoint in Saccharomyces cerevisiae both require Bir1. Mol Cell Biol. 2009;29(16):4552-4562.
9. Ruchaud S, Carmena M, Earnshaw WC. The chromosomal passenger complex: one for all and all for one. Cell. 2007;131(2):230-231.
10. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22(11):2729-2740.
11. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell. 2006;17(3):1483-1493.
12. Cheung CH, Sun X, Kanwar JR, Bai JZ, Cheng L, Krissansen GW. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int. 2010;10:36.
13. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-584.
14. Baratchi S, Kanwar RK, Cheung CH, Kanwar JR. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol. 2010;227(1-2):120-132.
15. Kanwar JR, Kanwar RK, Wang D, Krissansen GW. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol. 2000;78(6):641-645.
16. Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes future perspectives. Int J Pharm. 2013;440(1):48-62.
17. Mukherjee B, Santra K, Pattnaik G, Ghosh S. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine. 2008;3(4):487-496.
18. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93(20):1541-1552.
19. Rajapaksa TE, Stover-Hamer M, Fernandez X, Eckelhoefer HA, Lo DD. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release. 2010;142(2):196-205.
20. Messi E, Florian MC, Caccia C, Zanisi M, Maggi R. Retinoic acid reduces human neuroblastoma cell migration and invasiveness: effects on DCX, LIS1, neurofilaments-68 and vimentin expression. BMC Cancer. 2008;8:30.
21. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-2490.
22. Bilati U, Allémann E, Doelker E. Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J Microencapsul. 2005;22(2):205-214.
23. Gasper MM, Blanco D, Cruz ME, Alonso MJ. Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Control Release. 1998;52(1/2):53-62.
24. Nicoli S, Santi P, Couvreur P, Couarraze G, Colombo P, Fattal E. Design of triptorelin loaded nanospheres for transdermal iontophoretic administration. Int J Pharm. 2001;214(1/2):31-35.
25. Kumar G, Sharma S, Shafiq N, Khuller GK, Malhotra S. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci. 2012;101(6):2165-2176.
26. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond). 2007;2(2):219-232.
27. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76(2):189-199.
28. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29(10):3867-3875.
29. Ahmad A, Mukherjee P, Senapati S, et al. Extracellular biosynthesis of silver nanoparticles using the fungus Fusarium oxysporum. Colloids Surf B Biointerfaces. 2003;28(4):313-318.
30. Park H, Ko MY, Paik MK, Soh CT, Seo JH, Im KI. Cytotoxicity of a cysteine proteinase of adult Clonorchis sinensis. Korean J Parasitol. 1995;33(3):211-218.
31. Pitt CG. The controlled parenteral delivery of polypeptides and proteins. Int J Pharm. 1990;59(3):173-196.
32. Uchida T, Yagi A, Oda Y, Nakada Y, Goto S. Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres. Chem Pharm Bull (Tokyo). 1996;44(1):235-236.
33. Chen HB, Zheng Y, Tian G, et al. Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Res Lett. 2010;6(1):1-10.
34. Fernando LP, Kandel PK, Yu J, McNeill J, Ackroyd PC, Christensen KA. Mechanism of cellular uptake of highly fluorescent conjugated polymer nanoparticles. Biomacromolecules. 2010;11(10):2675-2682.
35. Lai SK, Wong CH, Lee YP, Li HY. Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death. Cell Death Differ. 2011;18(6):996-1004.
36. Li N, Nguyen HH, Byrom M, Ellington AD. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One. 2011;6(6):e20299.
37. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322.
38. Taupin P. BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation. Brain Res Rev. 2007;53(1):198-214.
39. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458-1461.
40. Kanwar JR, Sriramoju B, Kanwar RK. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine. 2012;7:3259-3278.
41. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151(7):1575-1582.
42. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33(4): 765-789.
43. Cheung CH, Sun X, Kanwar JR, Bai JZ, Cheng L, Krissansen GW. Correction: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int. 2010;10:43.
44. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003;9(3):931-946.
45. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer. 2002;38(17):2316-2324.
46. Krepela E, Dankova P, Moravcikova E, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol. 2009;35(6):1449-1462.
47. Dorta M, Munguía O, Llabres M. Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure. Int J Pharm. 1993;100(1/3):9-14.
48. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83(2):273-286.
49. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12(1):1-99.
50. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001;98(2):635-640.
51. Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest. 2001;108(7):991-999.
52. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33-42.
53. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000;97(24):13103-13107.
54. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459-470.
55. Freeman RS, Estus S, Johnson EM Jr. Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of cyclin D1 during programmed cell death. Neuron. 1994;12(2):343-355.
56. Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996;15(1):46-54.
57. Delvaeye M, De Vriese A, Zwerts F, et al. Role of the 2 zebrafish survivin genes in vasculo-angiogenesis, neurogenesis, cardiogenesis and hematopoiesis. BMC Dev Biol. 2009;9:25.
58. Villapol S, Acarin L, Faiz M, Castellano B, Gonzalez B. Survivin and heat shock protein 25/27 colocalize with cleaved caspase-3 in surviving reactive astrocytes following excitotoxicity to the immature brain. Neuroscience. 2008;153(1):108-119.
59. Rami A, Bechmann I, Stehle JH. Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog Neurobiol. 2008;85(3):273-296.
60. Trapp T, Korhonen L, Besselmann M, Martinez R, Mercer EA, Lindholm D. Transgenic mice overexpressing XIAP in neurons show better outcome after transient cerebral ischemia. Mol Cell Neurosci. 2003;23(2):302-313.
61. Miranda CJ, Braun L, Jiang Y, et al. Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-mediated surviving signaling. Aging Cell. 2012;11(3):542-552.
62. Rubio N, Garcia-Segura LM, Arevalo MA. Survivin prevents apoptosis by binding to caspase-3 in astrocytes infected with the BeAn strain of Theiler's murine encephalomyelitis virus. J Neurovirol. 2012;18(5):354-363.
63. Yan H, Thomas J, Liu T, et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene. 2006;25(52):6968-6974.
64. Wang JB, Qi LL, Zheng SD, Wu TX. Curcumin induces apoptosis through the mitochondria-mediated apoptotic pathway in HT-29 cells. J Zhejiang Univ Sci B. 2009;10(2):93-102.
65. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene. 2008;27(6):741-754.
66. Monga J, Pandit S, Chauhan CS, Sharma M. Cytotoxicity and apoptosis induction in human breast adenocarcinoma MCF-7 cells by (+)-cyanidan-3-ol. Exp Toxicol Pathol. 2013;65(7-8):1091-1100.
67. Ling Q, Xu X, Wei X, et al. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome C. J Exp Clin Cancer Res. 2011;30:66.
68. Li Y, Shibata Y, Zhang L, Kuboyama N, Abiko Y. Periodontal pathogen Aggregatibacter actinomycetemcomitans LPS induces mitochondria-dependent-apoptosis in human placental trophoblasts. Placenta. 2011;32(1):11-19.